Vernalis (OTCMKTS:VNLPY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Saturday. The firm presently has a $0.25 price objective on the stock. Zacks Investment Research‘s price target would indicate a potential downside of 3.85% from the stock’s current price.
According to Zacks, “Vernalis Group plc is a research and development-stage pharmaceutical company based in Oxford, UK, which is developing drugs for the treatment of unmet medical needs such as cancer and inflammatory and infectious diseases. The main technology platform is inhibition of metalloenzymes which will be supplemented through the addition of externally-generated programs. “
Shares of Vernalis (OTCMKTS:VNLPY) remained flat at $$0.26 during mid-day trading on Friday. Vernalis has a 1 year low of $0.26 and a 1 year high of $0.61.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/06/vernalis-vnlpy-upgraded-to-buy-by-zacks-investment-research.html.
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vernalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis and related companies with MarketBeat.com's FREE daily email newsletter.